MDI Therapeutics, Inc. is focused on developing innovative therapies aimed at treating fibrosis and fibroproliferative diseases. The company's lead program features a first-in-class orally available inhibitor of plasminogen activator inhibitor-1 (PAI-1), a key regulator in various pathological processes, including chronic fibrotic diseases. PAI-1 plays a crucial role in regulating fibrinolysis and wound healing by inhibiting tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA). The unique mechanism of PAI-1 allows it to act as a conformationally driven biological sensor, responding to specific enzymes that regulate cellular adhesion, migration, and proliferation. Despite the existence of numerous small molecules and antagonists targeting PAI-1, no approved drugs currently exist that directly inhibit this protein.

The scientific foundation of MDI Therapeutics is built upon key enabling technologies developed at the University of Michigan, where significant research has been conducted on the serpin family of proteins, including PAI-1. The company aims to leverage this research to advance its therapeutic candidates, addressing the inherent structural instability of PAI-1 that often leads to low-affinity and poorly specific drug candidates. MDI's approach is designed to overcome these challenges, potentially leading to more effective treatments for patients suffering from fibrotic diseases. The expertise of the company's team, which includes leaders in cardiovascular medicine and drug development, further supports its mission to innovate in this critical area of healthcare.

United States

Developing novel serpin-based therapies for the treatment of fibrosis and fibroproliferative disorders.

MDI Therapeutics, Inc.

Company Details